ArticleJournal of thoracic disease2025
The safety and effectiveness of immune checkpoint blockade in lung cancer with COPD: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of neoadjuvant chemoimmunotherapy on pulmonary function in non-small cell lung cancer patients.Translational lung cancer research · 2026Article
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- COPD-Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications.International journal of chronic obstructive pulmonary disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer with chronic obstructive pulmonary disease (COPD) often has a more aggressive invasion without manageable driver gene mutation. This study aimed to evaluate the safety and effectiveness of immune checkpoint blockade (ICB) in lung cancer with COPD. Methods: We searched for literature reporting immunotherapy in lung cancer with or without COPD in the PubMed, Web of Science, and Cochrane Library databases between January 2011 and July 2023. Five endpoints were evaluated: checkpoint inhibitor-related pneumonitis (CIP), objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Results: Eighteen studies were included. Lung cancer with COPD patients had a higher incidence of CIP (20.40% Conclusions: This meta-analysis showed that patients of lung cancer with COPD treated with ICB achieved longer survival and better radiologic response, but had a higher risk of CIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.